We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
User:Carson Powers/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 24: | Line 24: | ||
==ACE2 Receptor== | ==ACE2 Receptor== | ||
| - | <scene name='10/1076041/Ace2_only/2'>ACE2,</scene> the natural receptor for the spike protein, is a membrane-bound protein located in the lungs and made up of 805 amino acids. | + | <scene name='10/1076041/Ace2_only/2'>ACE2,</scene> the natural receptor for the spike protein, is a membrane-bound protein located in the lungs and made up of 805 amino acids. Its active site is located within a single extracellular N-terminal domain. <scene name='10/1076041/Ace2_interactions/3'>Residues 26-43 in this region form an alpha helix which makes the majority of interactions with the RBD of the spike protein. These interactions are stabilized by hydrogen bonding and van der Waals forces. </scene> |
| Line 35: | Line 35: | ||
==LCB== | ==LCB== | ||
| - | <scene name='10/1076042/Overall_lcb1_spike/3'>LCB1</scene>is a fully synthetic three-helix mini protein that acts as a competitive inhibitor, competing with ACE2 to bind to the spike protein. Unlike ABH2, <scene name='10/1076041/Lcb1_interactions/2'>a de novo design approach was taken to design LCB1, making it more compact with optimal interactions with the RBD.</scene> | + | <scene name='10/1076042/Overall_lcb1_spike/3'>LCB1</scene> is a fully synthetic three-helix mini protein that acts as a competitive inhibitor, competing with ACE2 to bind to the spike protein. Unlike ABH2, <scene name='10/1076041/Lcb1_interactions/2'>a de novo design approach was taken to design LCB1, making it more compact with optimal interactions with the RBD.</scene> |
Another mini protein inhibitor, <scene name='10/1076041/Lcb3_only/1'>LCB3,</scene> was developed using the same computational method as LCB1 and <scene name='10/1076042/Lcb3xspikecorlabel_intxn/1'>binds to the same region of the RBD, except in the opposite direction.</scene> However, LCB1 has more surface area and fits more precisely with its computational model, giving it a slightly higher binding affinity. | Another mini protein inhibitor, <scene name='10/1076041/Lcb3_only/1'>LCB3,</scene> was developed using the same computational method as LCB1 and <scene name='10/1076042/Lcb3xspikecorlabel_intxn/1'>binds to the same region of the RBD, except in the opposite direction.</scene> However, LCB1 has more surface area and fits more precisely with its computational model, giving it a slightly higher binding affinity. | ||
The LCBs have a significantly higher affinity for the spike RBD and are smaller and more stable than traditional antibodies. Their reduced size allows these molecules to tightly pack more interactions in the active site as well as improve their ability to enter the respiratory system. | The LCBs have a significantly higher affinity for the spike RBD and are smaller and more stable than traditional antibodies. Their reduced size allows these molecules to tightly pack more interactions in the active site as well as improve their ability to enter the respiratory system. | ||
| - | |||
Revision as of 02:20, 14 April 2025
De novo miniprotein Covid therapeutic
| |||||||||||
